Results 351 to 360 of about 225,115 (385)

Phosphodiesterases as therapeutic targets

Urology, 2003
The advent of sildenafil (Viagra) for the treatment of erectile dysfunction has attracted widespread interests in phosphodiesterase type 5 (PDE5), the target of sildenafil, 1 and other members of the PDE superfamily. PDEs are intracellular enzymes that catalyze the hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate ...
Guiting Lin, Zhongcheng Xin, Tom F. Lue, Ching-Shwun Lin   +3 more
openaire   +3 more sources

Phosphodiesterase-5 Inhibitors

2013
Nitric oxide (NO) signaling plays a key role in modulating vascular tone and remodeling in the pulmonary circulation. The guanylate cyclase/cyclic guanylate monophosphate-signaling pathway primarily mediates nitric oxide signaling. This pathway is critical in normal regulation of the pulmonary vasculature, and is an important target for therapy in ...
Barbara A. Cockrill, Aaron B. Waxman
openaire   +3 more sources

Phosphodiesterases in Asthma

1999
Airway obstruction and hyperreactivity in asthma are mainly caused by accumulation of inflammatory cells and their mediators promoting bronchoconstriction, airway oedema and airway remodeling. Cyclic AMP counteracts a huge variety of inflammatory cell functions involved in the development and maintenance of asthma.
Christian Schudt, Hermann Tenor
openaire   +2 more sources

An update on phosphodiesterase (PDE) inhibitors: Phosphodiesterases and drug selectivity

Methods and Findings in Experimental and Clinical Pharmacology, 2005
In recent years, there has been a prodigious expansion of knowledge about cyclic nucleotide phosphodiesterases (PDEs). This isozyme superfamily has now become a major focus of drug discovery efforts owing to its diversity, molecular nature, differential regulation and expression in different cell types, and the range of biological functions. Inhibition
Kumar G, Kumar Rs, Gupta R
openaire   +2 more sources

Pulmonary Responses to Selective Phosphodiesterase-5 and Phosphodiesterase-3 Inhibitors

Chest, 2004
To compare the direct pulmonary vasodilating activity and specificity of phosphodiesterase-5 (zaprinast) and phosphodiesterase-3 (milrinone) inhibitors on the pulmonary vascular (PV) bed of the spontaneously breathing cat with an intact chest.Prospective, randomized animal study.Laboratory of university hospital.Experiments were performed in vivo in ...
Yaacov Gozal, Idit Matot
openaire   +2 more sources

Carboxyamidotriazole: A novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases

European Journal of Pharmacology, 2015
Carboxyamidotriazole (CAI) is a non-cytotoxic anti-tumor drug, which also shows considerable anti-inflammatory effects in a variety of animal models of inflammation. The exact target and mechanism of CAI were not clearly understood yet. In the present study, we demonstrate that CAI is a non-selective phosphodiesterase (PDE) inhibitor, which provides ...
Lei Guo, Lifeng Luo, Rui Ju, Chen Chen, Lei Zhu, Juan Li, Xiaoli Yu, Caiying Ye, Dechang Zhang   +8 more
openaire   +3 more sources

Phosphodiesterases

2007
This chapter provides a thorough examination of the state of the art of phosphodiesterase enzymes (PDEs) and published inhibitors. There are a total of 11 known types of PDEs in the superfamily, PDE1–PDE11, and, within this group, there are a variety of subtypes and isoforms, some of which have unique function(s).
openaire   +2 more sources

Cyclic nucleotide phosphodiesterases

Journal of Allergy and Clinical Immunology, 2001
Cyclic nucleotide second messengers (cAMP and cGMP) play a central role in signal transduction and regulation of physiologic responses. Their intracellular levels are controlled by the complex superfamily of cyclic nucleotide phosphodiesterase (PDE) enzymes. Continuing advances in our understanding of the molecular pharmacology of these enzymes has led
openaire   +3 more sources

Tyrosyl‐DNA Phosphodiesterase (Tdp1) (3′‐Phosphotyrosyl DNA Phosphodiesterase)

2006
Tyrosyl-DNA phosphodiesterase (Tdp1) hydrolyzes 3'-phosphotyrosyl bonds in vitro. Because topoisomerase I, a type IB topoisomerase, is the only enzyme known to form 3'-phosphotyrosine bonds in eukaryotic cells, it was proposed that Tdp1 is involved in the repair of dead-end topoisomerase I-DNA covalent complexes that may form in vivo.
Alex B. Burgin, Amy C. Raymond
openaire   +3 more sources

Cyclic nucleotide phosphodiesterase in silkworm

Biochimica et Biophysica Acta (BBA) - Enzymology, 1975
The existence of cyclic GMP phosphodiesterase (EC 3.1.4.-) was demonstrated in silkworm larva by gel filtration of the homogenate. The cyclic GMP phosphodiesterase was separated from cyclic AMP phosphodiesterases by column chromatography on hydroxyapatite and Sephadex G-200. The enzyme has a molecular weight of approx.
openaire   +3 more sources